杨宁介入医学网

With more than 6,100 participants, the CIRSE annual meeting is the largest and most comprehensive forum for experts in image-guided minimally invasive therapies. The CIRSE Annual Congress and Postgraduate Course isa trend-setting, dynamic...

ECIO 2012 News Dont miss the deadline Our Early Bird registration deadline will only be available until February 16, 2012: Dont miss the chance to save to up 15% on the registration fee! REGISTER NOW! Accommodation The CIRSE Travel Service...

Colon Cancer Survival Improved With Use Of Oxaliplatin In 2011, about 101,340 Americans have been diagnosed with colon cancer, a leading worldwide cause of both illness and death, with around one third of cancers being diagnosed as stage I...

Colon Cancer Survival Improved With Use Of Oxaliplatin In 2011, about 101,340 Americans have been diagnosed with colon cancer, a leading worldwide cause of both illness and death, with around one third of cancers being diagnosed as stage I...

Colon Cancer Survival Improved With Use Of Oxaliplatin In 2011, about 101,340 Americans have been diagnosed with colon cancer, a leading worldwide cause of both illness and death, with around one third of cancers being diagnosed as stage I...

拜耳介入专家委员会在三亚召开 一年一度的拜耳介入专家委员会近日在三亚召开。与会的数十名来自全国的介入放射学领域的专家就下列议题进行了热烈的讨论。 （1）TACE联合索拉菲尼治疗肝癌的研究进展（中山大学附属第一医院 杨建勇） （2）肝癌治疗现状中国与...

Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Long-Term Outcome of Transcatheter Subsegmental and Segmental Arterial Chemoemobolization Using Lipiodol for Hepatocellular Carcinoma . Percutane...

靶向肿瘤治疗的病人因素 难治性脑动脉瘤新装置PED，获FDA批准（下图）...

第二届拜耳介入高峰论坛5月21日在杭州召开。 青岛大学医学院 梁军教授 抗肿瘤药物的临床研究 浙江肿瘤医院 邵国良教授 索拉菲尼治疗肝癌的最新数据 郑州大学第一附属医院 管生教授 肝癌疗效判定的新标准 mRECIST标准 解放军302医院 杨永平教授 合理选择病人...

球囊扩张式股动脉鞘：最小鞘剖面最大内径的股动脉鞘 FDA批准新的治疗脑动脉瘤装置...